Effects of intrapartum antimicrobial prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-onset neonatal sepsis

Lancet Infectious Diseases

Volumn 3, Issue 4, 2003, Pages 201-213

  Moore, Matthew R ^a,b   Schrag, Stephanie J ^b   Schuchat, Anne ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; PENICILLIN G;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; CORRELATION ANALYSIS; DRUG EFFECT; DRUG UTILIZATION; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HIGH RISK POPULATION; HUMAN; INCIDENCE; LOW BIRTH WEIGHT; NEWBORN SEPSIS; NONHUMAN; PATIENT MONITORING; PERINATAL PERIOD; PRACTICE GUIDELINE; PREMATURITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; VERY LOW BIRTH WEIGHT;

EID: 0037382165     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(03)00577-2     Document Type: Review

References (72)

1. Schendel DE, Schuchat A, Thorsen P. Public health issues related to infection in pregnancy and cerebral palsy. Ment Retard Dev Disabil Res Rev 2002; 8: 39-45.
2. Unhanand M, Mustafa MM, McCracken GH Jr, Nelson JD. Gram-negative enteric bacillary meningitis: a twenty-one-year experience. J Pediatr 1993; 122: 15-21.
3. Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs) Report: group B streptococcus. 2000. http://www.cdc.gov/ ncidod/dbmd/abcs (accessed Mar 10 2003).
4. Yow MD, Mason EO, Leeds LJ, Thompson PK, Clark DJ, Gardner SE. Ampicillin prevents intrapartum transmission of group B streptococcus. JAMA 1979; 241: 1245-47.
5. Boyer KM, Gadzala CA, Burd LI, Fisher DE, Paton JB, Gotoff SP. Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease: I epidemiologic rationale. J Infect Dis 1983; 148: 795-801.
6. Boyer KM, Gotoff SP. Prevention of early-onset neonatal group B streptococcal disease with selective intrapartum chemoprophylaxis. N Engl J Med 1986; 314: 1665-69.
7. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn: Guidelines for prevention of group B streptococcal (GBS) infection by chemoprophylaxis. Pediatrics 1992; 90: 775-78.
8. American College of Obstetrics and Gynecology. Group B streptococcal infections in pregnancy. Washington DC: American College of Obstetrics and Gynecology, 1992.
9. Centers for Disease Control and Prevention (USA). Prevention of perinatal group B streptococcal disease: a public health perspective. MMWR Recomm Rep 1996; 45: 1-24.
10. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn: revised guidelines for prevention of group B streptococcal (GBS) disease. Pediatrics 1997; 99: 489-86.
11. American College of Obstetricians and Gynecologists CoOP. Prevention of early-onset group B streptococcal disease in newborns. Washington DC: American College of Obstetricians and Gynecologists, 1996.
12. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B streptococcal disease: revised guidelines from CDC. MMWR Recomm Rep 2002; 51: 1-22.
13. Davis RL, Hasselquist MB, Cardenas V, et al. Introduction of the new Centers for Disease Control and Prevention group B streptococcal prevention guideline at a large West Coast health maintenance organization. Am J Obstet Gynecol 2001; 184: 603-10.
14. Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000; 342: 15-20.
15. Isaacs D, Royle JA. Intrapartum antibiotics and early onset neonatal sepsis caused by group B streptococcus and by other organisms in Australia. Pediatr Infect Dis J 1999; 18: 524-28.
16. Canadian Task Force on Preventive Health Care. Prevention of group B streptococcal infection in newborns: recommendation statement. Can Med Assoc J 2002; 166: 928-30.
17. McLaughlin K, Crowther C. Universal antenatal group B streptococcus screening? The opinions of obstetricians and neonatologists within Australia. Aust N Z J Obstet Gynaecol 2000; 40: 338-40.
18. Kieran E, Matheson M, Mann AG, Efstratiou AA, Butler K, Gorman W. Group B streptococcus (GBS) colonisation among expectant Irish mothers. Ir Med J 1998; 91: 21-22.
19. Stan CM, Boulvain M, Bovier PA, Auckenthaler R, Berner M, Irion O. Choosing a strategy to prevent neonatal early-onset group B streptococcal sepsis: economic evaluation. Br J Obstet Gynaecol 2001; 108: 840-47.
20. Bevilacqua G. [Prevention of perinatal infection caused by group B beta-hemolytic streptococcus]. Acta Biomed Ateneo Parmense 1999; 70: 87-94.
21. Bomela HN, Ballot DE, Cooper PA. Is prophylaxis of early-onset group B streptococcal disease appropriate for South Africa? S Afr Med J 2001; 91: 858-60.
22. Towers CV, Carr MH, Padilla G, Asrat T. Potential consequences of widespread antepartal use of ampicillin. Am J Obstet Gynecol 1998; 179: 879-83.
23. McDuffie RS Jr, McGregor JA, Gibbs RS. Adverse perinatal outcome and resistant Enterobacteriaceae after antibiotic usage for premature rupture of the membranes and group B streptococcus carriage. Obstet Gynecol 1993; 82: 487-89.
24. World Health Organization. Overcoming antimicrobial resistance. Geneva: WHO, 2000.
25. Stoll BJ, Hansen N, Fanaroff AA, et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med 2002; 347: 240-47.
26. Hyde TB, Hilger TM, Reingold A, Farley MM, O'Brien KL, Schuchat A. Trends in incidence and antimicrobial resistance of early-onset sepsis: population-based surveillance in San Francisco and Atlanta. Pediatrics 2002; 110: 690-95.
27. Baltimore RS, Huie SM, Meek JI, Schuchat A, O'Brien KL. Early-onset neonatal sepsis in the era of group B streptococcal prevention. Pediatrics 2001; 108: 1094-98.
28. Schrag S, Arnold K, Roome A, et al. Intrapartum antibiotic exposure in the era of perinatal group B streptococcal (GBS) disease prevention. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, USA, 2001: 280.
29. Anon. Early-onset group B streptococcal disease United States, 1998-1999. MMWR Morb Mortal Wkly Rep 2000; 49: 793-96.
30. Landry L, Richardson S, Matlow A, et al. Incidence of neonatal sepsis due to gram-negative bacteria in Toronto, Canada, 1996-1999. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000: 446.
31. Soriano-Gabarro M, Butler JC, Jacob J, et al. Epidemiology of neonatal sepsis caused by group B streptococci and other bacterial pathogens among Alaska newborns. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 16-20; Toronto, Canada.
32. Lieu TA, Mohle-Boetani JC, Ray GT, Ackerson LM, Walton DL. Neonatal group B streptococcal infection in a managed care population. Obstet Gynecol 1998; 92: 21-27.
33. Towers CV, Briggs GG. Antepartum use of antibiotics and early-onset neonatal sepsis: the next 4 years. Am J Obstet Gynecol 2002; 187: 495-500.
34. Wendel GD Jr, Leveno KJ, Sanchez PJ, Jackson GL, McIntire DD, Siegel JD. Prevention of neonatal group B streptococcal disease: a combined intrapartum and neonatal protocol. Am J Obstet Gynecol 2002; 186: 618-26.
35. Chen KT, Tuomala RE, Cohen AP, Eichenwald EC, Lieberman E. No increase in rates of early-onset neonatal sepsis by non-group B streptococcus or ampicillin-resistant organisms. Am J Obstet Gynecol 2001; 185: 854-58.
36. Main EK, Slagle T. Prevention of early-onset invasive neonatal group B streptococcal disease in a private hospital setting: the superiority of culture-based protocols. Am J Obstet Gynecol 2000; 182: 1344-54.
37. Reisner DP, Haas MJ, Zingheim RW, Williams MA, Luthy DA. Performance of a group B streptococcal prophylaxis protocol combining high-risk treatment and low-risk screening. Am J Obstet Gynecol 2000; 182: 1335-43.
38. Brozanski BS, Jones JG, Krohn MA, Sweet RL. Effect of a screening-based prevention policy on prevalence of early- onset group B streptococcal sepsis. Obstet Gynecol 2000; 95: 496-501.
39. Cordero L, Sananes M, Ayers LW. Bloodstream infections in a neonatal intensive-care unit: 12 years' experience with an antibiotic control program. Infect Control Hosp Epidemiol 1999; 20: 242-46.
40. Levine EM, Ghai V, Barton JJ, Strom CM. Intrapartum antibiotic prophylaxis increases the incidence of gram-negative neonatal sepsis. Infect Dis Obstet Gynecol 1999; 7: 210-13.
41. Jeffery HE, Moses Lahra M. Eight-year outcome of universal screening and intrapartum antibiotics for maternal group B streptococcal carriers. Pediatrics 1998; 101: E2.
42. Factor SH, Levine OS, Nassar A, et al. Impact of a risk-based prevention policy on neonatal group B streptococcal disease. Am J Obstet Gynecol 1998; 179: 1568-71.
43. Joseph TA, Pyati SP, Jacobs N. Neonatal early-onset Escherichia coli disease: the effect of intrapartum ampicillin. Arch Pediatr Adolesc Med 1998; 152: 35-40.
44. Gibbs RS, McDuffie RS Jr, McNabb F, Fryer GE, Miyoshi T, Merenstein G. Neonatal group B streptococcal sepsis during 2 years of a universal screening program. Obstet Gynecol 1994; 84: 496-500.
45. Andrews JI, Diekema DJ, Hunter SK, et al. Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the western hemisphere. Am J Obstet Gynecol 2000; 183: 859-62.
46. Lin FY, Azimi PH, Weisman LE, et al. Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995-1998. Clin Infect Dis 2000; 31: 76-79.
47. Bland ML, Vermillion ST, Soper DE, Austin M. Antibiotic resistance patterns of group B streptococci in late third-trimester rectovaginal cultures. Am J Obstet Gynecol 2001; 184: 1125-26.
48. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis 2002; 34: 1558-63.
49. Harris AD. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001; 32: 1055-61.
50. Harris AD, Samore MH, Carmeli Y. Control group selection is an important but neglected issue in studies of antibiotic resistance. Ann Intern Med 2000; 133: 159.
51. Lipsitch M. Measuring and interpreting associations between antibiotic use and penicillin resistance in Streptococcus pneumoniae. Clin Infect Dis 2001; 32: 1044-54.
52. Mercer BM, Carr TL, Beazley DD, Crouse DT, Sibai BM. Antibiotic use in pregnancy and drug-resistant infant sepsis. Am J Obstet Gynecol 1999; 181: 816-21.
53. Schuchat A, Zywicki SS, Dinsmoor MJ, et al. Risk factors and opportunities for prevention of early-onset neonatal sepsis: a multicenter case-control study. Pediatrics 2000; 105: 21-26.
54. Terrone DA, Rinehart BK, Einstein MH, Britt LB, Martin JN Jr, Perry KG. Neonatal sepsis and death caused by resistant Escherichia coli: possible consequences of extended maternal ampicillin administration. Am J Obstet Gynecol 1999; 180: 1345-48.
55. Kenyon SL, Taylor DJ, Tarnow-Mordi W. Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. Lancet 2001; 357: 989-94.
56. Kenyon SL, Taylor DJ, Tarnow-Mordi W. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes. ORACLE Collaborative Group. Lancet 2001; 357: 979-88.
57. Benitz WE, Gould JB, Druzin ML. Risk factors for early-onset group B streptococcal sepsis: estimation of odds ratios by critical literature review. Pediatrics 1999; 103: e77.
58. Eichenwald EC. Perinatally transmitted neonatal bacterial infections. Infect Dis Clin North Am 1997; 11: 223-39.
59. Edwards RK, Clark P, Sistrom CL, Duff P. Intrapartum antibiotic prophylaxis: I relative effects of recommended antibiotics on gram-negative pathogens. Obstet Gynecol 2002; 100: 534-39.
60. Spaetgens R, DeBella K, Ma D, Robertson S, Mucenski M, Davies HD. Perinatal antibiotic usage and changes in colonization and resistance rates of group B streptococcus and other pathogens. Obstet Gynecol 2002; 100: 525-33.
61. Allen SR. Management of asymptomatic term neonates whose mothers received intrapartum antibiotics - part 2: diagnostic tests and management strategies. Clin Pediatr (Phila) 1997; 36: 617-24.
62. Martin JA HB, Ventura SJ, Menacker F, Park MM. Births: final data for 2000. Hyattsville, MD: National Center for Health Statistics, 2002.
63. Cararach V, Botet F, Sentis J, Almirall R, Perez-Picanol E. Administration of antibiotics to patients with rupture of membranes at term: a prospective, randomized, multicentric study. Acta Obstet Gynecol Scand 1998; 77: 298-302.
64. Bar J, Maayan-Metsger A, Hod M, et al. Effect of antibiotic therapy in preterm premature rupture of the membranes on neonatal mortality and morbidity. Am J Perinatol 2000; 17: 237-41.
65. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA 1999; 281: 736-38.
66. Slattery MM, Morrison JJ. Preterm delivery. Lancet 2002; 360: 1489-97.
67. Goldenberg RL. The management of preterm labor. Obstet Gynecol 2002; 100: 1020-37.
68. Kasper D, Paoletti L, Wessels M. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996; 98: 2308-14.
69. Baker C, Paoletti L, Wessels M. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. J Infect Dis 1999; 179: 142-50.
70. Baker C, Paoletti L, Rench M. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B streptococcus in healthy women. J Infect Dis 2000; 182: 1129-38.
71. Robbins J, Schneerson R, Vann W, Bryla D, Fattom A. Prevention of systemic infections caused by group B streptococcus and Staphylococcus aureus by multivalent polysaccharide-protein conjugate vaccines. Ann NY Acad Sci 1995; 754: 68-82.
72. Schuchat A, Deaver-Robinson K, Plikaytis BD, Zangwill KM, Mohle-Boetani J, Wenger JD. Multistate case-control study of maternal risk factors for neonatal group B streptococcal disease. Pediatr Infect Dis J 1994; 13: 623-29.